Effects of Atorvastatin on Reducing F-FDG Accumulation in Atherosclerotic Plaques: Using PET Imaging Study: pilot phase

Effects of Atorvastatin on Reducing F-FDG Accumulation in Atherosclerotic Plaques: Using PET Imaging Study: pilot phase - EARDROP Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000371

Enrollment

Registered

2006-09-01

Start date

2006-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with hyperlipidemia, who are going to undergo percutaneous coronary intervention for treatment of stable angina pectoris

Interventions

Patients are given low doses (5 mg/day) atorvastatin for 6 months, starting immediately after PCI Patients are given high doses (20 mg/day) atorvastatin for 6 months, starting immediately after PCI

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with hyperlipidemia who are taking elective PCI

Exclusion criteria

Exclusion criteria: 1)Patients with impaired glucose tolerance or diabetes mellitus 2)Patients with serum Cr>2mg/dl 3)Patients with acute coronary syndrom 4)Patients who are treated with any lipid-lowering drugs (statins, fibrates and/or nicotinic acid) before enrollment

Design outcomes

Primary

Measure	Time frame
Changes in the F-FDG-accumulation rate (plaque/integral plasma) at 6 months after PCI from baseline (both absolute value and % changes)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026